GlaxoSmithKline plc (NYSE:GSK) Plans Quarterly Dividend of $0.49

GlaxoSmithKline plc (NYSE:GSK) announced a quarterly dividend on Thursday, July 30th, Wall Street Journal reports. Shareholders of record on Friday, August 14th will be paid a dividend of 0.4914 per share by the pharmaceutical company on Thursday, October 8th. This represents a $1.97 dividend on an annualized basis and a yield of 4.88%. The ex-dividend date of this dividend is Thursday, August 13th. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.47.

GlaxoSmithKline has decreased its dividend by an average of 2.1% annually over the last three years and has increased its dividend every year for the last 1 years. GlaxoSmithKline has a payout ratio of 78.0% meaning its dividend is currently covered by earnings, but may not be in the future if the company’s earnings fall. Analysts expect GlaxoSmithKline to earn $2.96 per share next year, which means the company should continue to be able to cover its $2.24 annual dividend with an expected future payout ratio of 75.7%.

NYSE:GSK opened at $40.32 on Friday. GlaxoSmithKline has a 12-month low of $31.43 and a 12-month high of $48.25. The firm has a market capitalization of $100.97 billion, a price-to-earnings ratio of 11.96, a P/E/G ratio of 4.49 and a beta of 0.70. The stock’s 50 day moving average price is $40.90 and its two-hundred day moving average price is $41.54. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 1.28.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, April 29th. The pharmaceutical company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.18. GlaxoSmithKline had a return on equity of 31.21% and a net margin of 19.03%. The business had revenue of $11.64 billion during the quarter, compared to the consensus estimate of $10.95 billion. Equities research analysts expect that GlaxoSmithKline will post 3.12 EPS for the current year.

In related news, Director Plc Glaxosmithkline purchased 361,111 shares of GlaxoSmithKline stock in a transaction that occurred on Tuesday, July 21st. The shares were acquired at an average price of $18.00 per share, with a total value of $6,499,998.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.00% of the stock is currently owned by insiders.

Several analysts recently commented on the stock. Barclays reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a report on Thursday, April 30th. ValuEngine downgraded GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, May 5th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold”.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Why do corrections happen?

Dividend History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.